The lateral septum is a key brain region where GLP-1 peptide receptor activation modulates food intake, integrating both hunger-driven and pleasure-driven eating.
Dual feeding circuit integrationThe lateral septum uniquely integrates both homeostatic (need-based) and hedonic (reward-based) feeding pathways, and GLP-1 receptor activation in this region modulates food intake.
What the researchers found
The lateral septum serves as a neural relay center integrating homeostatic (nutritional need-driven) and hedonic (pleasure-driven) feeding circuits. GLP-1 receptors are present in the LS, and their activation within this region modulates food intake. The extensive neural connections between the LS and other brain regions involved in feeding behavior position it as a critical node where GLP-1 signaling may influence eating through multiple pathways simultaneously.
Why it matters
GLP-1 receptor agonists like semaglutide are among the most effective obesity treatments available, but exactly how they reduce appetite in the brain is still being mapped out. Identifying the lateral septum as an important site of GLP-1 action advances our understanding of these drugs' mechanisms and could help develop more targeted or effective future therapies.
How the study worked
This is a narrative review synthesizing recent findings on the lateral septum's role in feeding regulation and the GLP-1/GLP-1R system within this brain region. The authors draw on neuroanatomical, neurochemical, and behavioral studies to build their argument.
What this study cannot tell us
As a narrative review, this paper synthesizes existing evidence but does not present new experimental data. Much of the evidence for GLP-1R function in the lateral septum comes from animal models, and direct human evidence is limited. The review advocates for future research rather than providing definitive conclusions about the LS as a therapeutic target.
How to read the evidence
This is a narrative review of primarily preclinical literature. While it identifies an important research direction, the evidence for GLP-1R in the lateral septum as a therapeutic target is largely from animal studies and has not yet been validated clinically.
When this study was published
Published in 2025, this review captures the latest understanding of brain GLP-1 signaling during the height of clinical interest in GLP-1 receptor agonists for obesity.
The bigger picture
GLP-1 receptor agonists have transformed obesity treatment, but the field is still discovering exactly where in the brain these drugs act. Most attention has focused on hypothalamic and brainstem regions. This review highlights the lateral septum as an underappreciated but important target, adding a new dimension to our understanding of how peptide hormones regulate eating behavior through distributed brain networks.
Questions still open
- Do current GLP-1 receptor agonist drugs like semaglutide actually reach and act on receptors in the lateral septum in humans?
- Could targeted delivery of GLP-1 agonists to the lateral septum produce more specific appetite suppression with fewer side effects?
- How does GLP-1 signaling in the lateral septum interact with reward-driven overeating specifically?
Common questions
What is the lateral septum and why does it matter for appetite?
How does this relate to weight-loss drugs like Ozempic and Wegovy?
Read the original research
Lateral Septum as a Key Integrative Regulator of Feeding: Role of the GLP-1/GLP-1R System.
Journal of neurochemistry, 169(11), e70301
Citation
Dib, Tatiana; Covarrubias, María José; Escobar, Angélica; Renard, Georgina M; Bravo, Javier A; Sotomayor-Zárate, Ramón. (2025). Lateral Septum as a Key Integrative Regulator of Feeding: Role of the GLP-1/GLP-1R System.. Journal of neurochemistry, 169(11), e70301. https://doi.org/10.1111/jnc.70301